Acro Biomedical Co., Ltd. (OTC: ACBM)

Acro Biomedical Co., Ltd. focuses on the development and marketing of nutritional products designed to promote wellness and a healthy lifestyle. The company operates within the dietary supplements industry, with a primary emphasis on products derived from cordyceps, a fungus used in traditional Chinese medicine. Cordyceps sinensis, a rare combination of a caterpillar and a fungus, is found at high altitudes and has been documented in old Chinese medical books and Tibetan medicine. The company's business plan is in its preliminary stages, requiring significant funding to implement its strategies, with no guarantee of success.

Revenue generation for Acro Biomedical Co., Ltd. has historically come from the purchase of cordyceps-related products from suppliers in the Republic of China (Taiwan). The company's primary product is cordyceps, which it sells to customers who either resell the product in its purchased form or use it as an ingredient in their own products. Additionally, the company has sold metallothionein MT-3 elizer, although it is not clear whether this product is considered a core part of its business. The customer base primarily consists of distributors who purchase products in bulk.

• Cordyceps Segment: This segment focuses on the development, marketing, and sale of cordyceps-related products. Cordyceps is a key ingredient in traditional Chinese medicine and is marketed for its potential health benefits. The company has historically sold cordyceps products to customers who use them as ingredients in their own products or resell them. The market for this segment includes both domestic and international customers, particularly in Asia.

• Metallothionein MT-3 Elizer Segment: In the quarter ended June 30, 2018, the company sold metallothionein MT-3 elizer. However, it is unclear whether this product is considered a core part of the business or if it was a one-time sale. The market for this segment is not well-defined in the provided information.

Acro Biomedical Co., Ltd. operates in a competitive industry with several key players. In the United States, competitors include Real Mushrooms, Bulk Supplements, Terrasoul SuperFoods, Mental Refreshment Nutrition, NOW Foods, Aloha Medicinals, Natures Elements, and Swanson Premium. These companies market a variety of cordyceps products, including extracts and combinations with other ingredients. Many of these competitors are better known and better capitalized than Acro Biomedical Co., Ltd., posing a significant challenge for the company's competitive positioning. Additionally, there are numerous companies marketing cordyceps products in Asia, further intensifying competition. The company's competitive advantages are not explicitly stated, but it may rely on the quality of its cordyceps products and its ability to develop complementary products.

The company's customers primarily consist of distributors who purchase cordyceps products in bulk. These distributors are responsible for complying with applicable regulations in the countries where they sell the products, including Taiwan, China, and Hong Kong. The specific names of customers are not provided in the filing, but the general customer base includes businesses that use cordyceps as an ingredient in their own products or resell them. The company has not sold products directly to consumers, focusing instead on bulk sales to distributors.